en · de · es · fr · pt
melanotan-2-notes.peptides4088.com › Data › Melanotan-2 Structure And Receptor Pharmacology — Worked Examples

Melanotan-2 Structure And Receptor Pharmacology — Worked Examples

By Editorial Desk · published 2025-09-17 · last reviewed 2025-10-07 · Data

This is a working overview of alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-10-07 and is reviewed periodically as new material appears.

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Background and Mechanism of Melanotan-2

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms add to total mass
Molecular massAbout 1024 daltonsCalculated for the free base
Structural classCyclic heptapeptideContains D-phenylalanine and norleucine
Parent hormoneAlpha-melanocyte-stimulating hormoneEndogenous tridecapeptide of 13 residues
Receptor profileNon-selective melanocortin agonistInteracts with MC1R, MC3R, MC4R and MC5R

Melanotan-2 Identity and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Related pages on this site

Origins and Research Status

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Reference notes

=== Classic physique === This is the middle ground of Men's Physique and Bodybuilding, a category that emphasizes symmetry, proportion, pleasing lines, and a small waist over size and mass. The competitors in this category are not nearly as big as Open class bodybuilders but not as small as Men's Physique competitors. They pose and perform in men's boxer briefs or posing trunks to show off the legs as in the Open class, unlike Men's Physique which hide the legs in board shorts. The judging criteria also looks to see certain poses emphasized, such as ones accentuating the vacuum to illustrate a tapered torso and lack of the infamous bloated gut of Open bodybuilding.

== History == This methodology was first published in 1996 by a lab at Stanford University. Previous attempts to quantify antigen-specific T-cells involved the less accurate limiting dilution assay, which estimates numbers of T-cells at 50-500 times below their actual levels. Stains using soluble MHC monomers were also unsuccessful due to the low binding affinity of T-cell receptors and MHC-peptide monomers. MHC tetramers can bind to more than one receptor on the target T-cell, resulting in an increased total binding strength and lower dissociation rates.

The outer layer, or subintima, can be of almost any type of connective tissue – fibrous (dense collagenous type), adipose (fatty; e.g. in intra-articular fat pads) or areolar (loose collagenous type). The inner layer (in contact with synovial fluid), or intima, consists of a sheet of cells thinner than a piece of paper. Where the underlying subintima is loose, the intima sits on a pliable membrane, giving rise to the term synovial membrane. This membrane, together with the cells of the intima, provides something like an inner tube, sealing the synovial fluid from the surrounding tissue (effectively stopping the joints from being squeezed dry when subject to impact, such as running). Just outside the intima, most synovium has a dense net of fenestrated small blood vessels that provide nutrients not only for synovium but also for the avascular cartilage. In any one position, much of the cartilage is close enough to get nutrition directly from the synovium. Some areas of cartilage have to obtain nutrients indirectly and may do so either from diffusion through cartilage or possibly by 'stirring' of synovial fluid. The surface of synovium may be flat or may be covered with finger-like projections or villi, which, it is presumed, help to allow the soft tissue to change shape as the joint surfaces move one on another. The synovial fluid can be thought of as a specialized fluid form of synovial extracellular matrix rather than a secretion in the usual sense.

Sources: en.wikipedia.org

Reference notes

During his tenure with the X-Men, Wolverine becomes a mentor for Kitty Pryde and later on Jubilee. Logan again encounters Jean, who has been resurrected and re-joins the X-Men, leading to resumption of Logan's rivalry with Cyclops. He is able to recall some of the trauma he received from the Weapon X program and tries to investigate his past, although his memories remain unreliable because of brainwashing and false memory implants. He meets Maverick, another former participant in the Weapon X project, and discovers that he had previously worked together with Sabretooth in Team X. During a conflict, the supervillain Magneto forcibly removes the adamantium from Wolverine's skeleton. This massive trauma causes his healing factor to burn out and leads to the discovery that his claws are actually bone. Wolverine leaves the X-Men for a time, embarking on a series of adventures during which his healing factor returns. After his return to the X-Men, Cable's son Genesis kidnaps Wolverine and attempts to re-bond adamantium to his skeleton. This is unsuccessful and causes Wolverine's mutation to accelerate out of control. He degenerates physically and mentally into a more primitive, bestial state. Elektra helps him to recover his humanity. Eventually, the villain Apocalypse captures Wolverine, brainwashes him into becoming the Horseman of Death, and successfully re-bonds adamantium to his skeleton. Wolverine overcomes Apocalypse's programming and returns to the X-Men.

== Research == As of October 2025, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia and Alzheimer's disease. It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication. Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals. Seltorexant is being explored at doses of 5 to 80 mg. In the early clinical trials conducted so far, seltorexant has been found to improve depression scores on the Hamilton Depression Rating Scale in people with MDD and to improve sleep onset, total sleep time, time awake after sleep onset, and sleep efficiency in people with MDD and/or insomnia.

Poor milk intake can be caused by poor milk transfer by the infant or by true low milk supply by the mother. When the milk "comes in" appropriately, but is followed by decreased milk supply, this is most often caused by allowing milk to remain in the breasts for long periods of time, or insufficiently draining the breasts during feeds. If the baby is latching and swallowing well (signs of good milk transfer), but is not gaining weight as expected or is showing signs of dehydration, low milk supply in the mother can be suspected, and a lactation specialist should be consulted.

Sources: en.wikipedia.org

Notes from published material

==== 3.E. Light absorption-driven transporters ==== Bacteriorhodopsin-like proteins including rhodopsin (see also opsin) Bacterial photosynthetic reaction centres and photosystems I and II Light harvesting complexes from bacteria and chloroplasts

=== Disappearance === On 4 March 1998, at around 2:00 PM, Mendonça took his bicycle and cycled to his mother's workplace, located near the family home. He had asked his mother for permission to spend the afternoon riding in a car "with his friend Afonso" (Afonso Dias), a 22-year-old lorry driver. Mendonça's mother denied the request, and told him to go play in an abandoned lot outside her office.

=== Other cultures === Scorpions are among the many animals modelled in the art of the Moche culture of Peru. Mimbres artists in the south of New Mexico created painted ceramics of scorpions and many other symbolic and mythological animals on funerary bowls. A hole was ritually punched through the bottom of the bowl to "kill" it during a funeral.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

How does melanotan-2 differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.

What is the connection to alpha-MSH?

Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Network